profit from every DKK 100 of sales.
DKK 0DKK 100
GN Store Nord
DKK 119.35-2.13% today
+9.9% in 1 year
1-year low DKK 86.501-year high DKK 124.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay DKK 26.61 for every DKK 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What GN Store Nord sold, what it kept, and what it did with the cash.
Sales went from DKK 18.7 billion in 2022 to DKK 16.8 billion in 2025, with DKK 653 million of profit last year.
SalesProfit
GN Store Nord handed back 7% of the cash it generated last year.
DKK 85M
Free cash flow 2025DKK 1.1B
Bought back its own shares–
Paid as dividendsDKK 85M
Cash vs. debtDKK 1.1B vs. DKK 10.8B
GN Store Nord vs. similar companies
GN Store Nord grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from DKK 100 of sales | Sales growth a year | Price per DKK 1 of profit |
|---|---|---|---|
| GN Store Nord | 26.6× · Fair price | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads GN Store Nord's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of DKK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 18,687 | 18,120 | 17,985 | 16,782 | |
| 9,132 | 8,945 | 9,564 | 9,157 | |
| 1,120 | 943 | 1,788 | 1,598 | |
| 2,445 | 2,398 | 3,119 | 2,646 | |
| 511 | 228 | 988 | 653 | |
| 3.99 | 1.64 | 6.78 | 4.48 | |
| 48.9% | 49.4% | 53.2% | 54.6% | |
| 6.0% | 5.2% | 9.9% | 9.5% | |
| 2.7% | 1.3% | 5.5% | 3.9% |
Balance sheet
| In millions of DKK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 30,589 | 30,642 | 30,611 | 29,226 |
| Cash | 990 | 2,162 | 980 | 1,119 |
| Total debt | 16,253 | 13,499 | 11,487 | 10,815 |
| Total liabilities | 23,789 | 21,055 | 19,787 | 18,328 |
| 6,800 | 9,587 | 10,824 | 10,898 | |
| 128 | 139 | 146 | 146 | |
| 3.1% | 2.3% | 6.2% | 4.8% | |
| 7.5% | 2.4% | 9.1% | 6.0% |
Cash flow
| In millions of DKK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 627 | 2,638 | 2,725 | 2,676 | |
| 1,668 | 1,432 | 1,404 | 1,539 | |
| -1,041 | 1,206 | 1,321 | 1,137 | |
| Dividends paid | 208 | 32 | – | 85 |
| 0 | – | – | – | |
| 111 | 18 | -36 | -41 |
Valuation
- 26.6×
- –
- 6.76
- 1.6×
- 1.0×
- 15.3×
- 10.2×
- 6.5%
- 3.8%
- 0.5%
Profitability
- 54.6%
- 9.5%
- 3.9%
- –
- 4.7%
- 4.0%
- –
- –
- –
- –
Growth
- −3.5%
- +3.9%
- –
- –
- +4.4%
Financial health
- 3.7×
- 0.99
- –
- 3.3×
- 1.18
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 43%of 963
Bottom 48%of 894
Top 48%of 632
Bottom 12%of 908
Top 16%of 991
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
13.0% of its profit
Room to growStretchedMore than it earns: 7.5%
News
Black Rock Coffee Bar raises its full-year store growth targetSeeking Alpha · Nov 11, 2026American Healthcare REIT forecasts $2.23-$2.26 2026 NFFO per share as same-store NOI growth target rises to 12%-14%Seeking Alpha · Nov 6, 2026Havertys expects 2026 gross margins of 61.3% to 61.5% while planning 5 Q4 store openingsSeeking Alpha · Nov 4, 2026UDR signals 80-100 bps 2027 same-store revenue earn-in as $2B Apollo JV closesSeeking Alpha · Nov 3, 2026CaixaBank enables Apple Pay instalments for in-store purchasesYahoo Finance · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
55No pass
Philip Fisher
38No pass
Peter Lynch
14No pass
Joel Greenblatt
20No pass
Charlie Munger
24No pass
Terry Smith
32No pass
Questions about GN Store Nord
Is GN Store Nord a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the GN Store Nord AI analysis
What does GN Store Nord do?
GN Store Nord A/S provides hearing, audio, video, and gaming solutions in Denmark, Europe, North America, and internationally. The company operates through Hearing, Enterprise, and Gaming segments. The Hearing segment produces and sells hearing instruments and products. It is in Medical Devices, based in Ballerup, Denmark, with 7,736 employees.
Does GN Store Nord pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 13% of its yearly profit. In 2025 it paid out DKK 85.0 million in dividends.
Is GN Store Nord stock halal?
No. GN Store Nord does not pass our halal screen: its debt is 62% of its market value, at or above the 33% limit. How we check
How has GN Store Nord stock done over the past year?
Up 9.9% over the past twelve months, to DKK 119.35. It traded between DKK 86.50 and DKK 124.00 and is 3.8% below its high.
Who are GN Store Nord's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with GN Store Nord's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.